Skip to content

Kimberly M Lovell

6 papers in the library · 135 citations · publishing 2009-2013

Papers

Sort Most recent Most cited

LC-MS/MS quantification of salvinorin A from biological fluids.

Analytical methods : advancing methods and applications December 21, 2013 Michael J Caspers, Todd D Williams, Kimberly M Lovell et al. 6 citations

A facile method for quantifying the concentration of the powerful and widely available hallucinogen salvinorin A (a selective kappa opioid agonist) from non-human primate cerebrospinal fluid (CSF) and human plasma has been developed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in positive electrospray ionization (ESI) mode. With CSF solid phase extraction can be avoided...

Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.

The Journal of pharmacology and experimental therapeutics June 1, 2012 Eduardo R Butelman, Michael J Caspers, Kimberly M Lovell et al. 27 citations

Active blood-brain barrier mechanisms, such as the major efflux transporter P-glycoprotein (mdr1), modulate the in vivo/central nervous system (CNS) effects of many pharmacological agents, whether they are used for nonmedical reasons or in pharmacotherapy. The powerful, widely available hallucinogen salvinorin A (from the plant Salvia divinorum) is a high-efficacy, selective κ-opioid agonist...

Semisynthetic neoclerodanes as kappa opioid receptor probes.

Bioorganic & medicinal chemistry May 1, 2012 Kimberly M Lovell, Tamara Vasiljevik, Juan J Araya et al. 35 citations

Modification of the furan ring of salvinorin A (1), the main active component of Salvia divinorum, has resulted in novel neoclerodane diterpenes with opioid receptor affinity and activity. Conversion of the furan ring to an aldehyde at the C-12 position (5) has allowed for the synthesis of analogues with new carbon-carbon bonds at that position. Previous methods for forming these bonds, such as...

Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A.

MedChemComm December 1, 2011 Katherine M Prevatt-Smith, Kimberly M Lovell, Denise S Simpson et al. 50 citations

Previous structure-activity relationship studies of salvinorin A have shown that modification of the acetate functionality off the C-2 position to a methoxy methyl or methoxy ethyl ether moiety leads to increased potency at KOP receptors. However, the reason for this increase remains unclear. Here we report our efforts towards the synthesis and evaluation of C-2 constrained analogs of...

Synthesis of neoclerodane diterpenes and their pharmacological effects.

Topics in current chemistry 2011 Kimberly M Lovell, Katherine M Prevatt-Smith, Anthony Lozama et al. 17 citations

Salvinorin A is a neoclerodane diterpene that has been shown to be an agonist at kappa opioid receptors. Its unique structure makes it an attractive target for synthetic organic chemists due to its seven chiral centers and diterpene scaffold. This molecule is also interesting to pharmacologists because it is a non-serotonergic hallucinogen, and the first opioid ligand discovered that lacks a...

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.

Organic & biomolecular chemistry September 21, 2009 Denise S Simpson, Kimberly M Lovell, Anthony Lozama et al.

Further synthetic modification of the furan ring of salvinorin A (1), the major active component of Salvia divinorum, has resulted in novel neoclerodane diterpenes with opioid receptor affinity and activity. A computational study has predicted 1 to be a reproductive toxicant in mammals and is suggestive that use of 1 may be associated with adverse effects. We report in this study that...